182|275|Public
25|$|Taurine {{has been}} {{investigated}} in animal studies {{as an alternative to}} glucose as an osmotic agent for use in peritoneal <b>dialysis</b> <b>solutions.</b>|$|E
50|$|The first {{documented}} case of nodularin poisoning was {{an animal}} (sheep) in Australia in 1878. The chemical structure of Nodularin-R was identified in 1988. In Caruaru, Brazil in 1996, <b>dialysis</b> <b>solutions</b> {{from a local}} reservoir were contaminated with blue-green algae. Patients receiving hemodialysis were exposed to these solutions, 100 of 131 developed acute liver failure and 52 / 131 patients died after developing toxic hepatitis.|$|E
50|$|In April 2002, the Snia Group {{acquired}} from Dialinvest S.A. control of Soludia, a French company {{specializing in the}} manufacture of <b>dialysis</b> <b>solutions,</b> thereby strengthening the product portfolio and European presence of the Renal Care Business Unit. In January 2003, the Snia Group bought from Centerpulse the CarboMedics Group, a U.S. producer of mechanical heart valves based in Austin, Texas, and Mitroflow, a Canadian-based producer of tissue valves. This acquisition significantly strengthened the position of the Sorin Group in the cardiovascular industry and increased its penetration of the U.S. market. In addition, the acquisition made Sorin the world co-leader in mechanical heart valves and significantly expanded its tissue valve business.|$|E
5000|$|Intraperitoneal <b>dialysis</b> <b>solution</b> (of {{appropriate}} composition) ...|$|R
50|$|Once {{purified}} water {{is mixed with}} dialysate concentrate, its conductivity increases, since water that contains charged ions conducts electricity. During dialysis, the conductivity of <b>dialysis</b> <b>solution</b> is continuously monitored {{to ensure that the}} water and dialysate concentrate are being mixed in the proper proportions. Both excessively concentrated <b>dialysis</b> <b>solution</b> and excessively dilute solution can cause severe clinical problems.|$|R
50|$|The <b>dialysis</b> <b>{{solution}}</b> {{that is used}} may be a sterilized {{solution of}} mineral ions. Urea and other waste products, potassium, and phosphate diffuse into the <b>dialysis</b> <b>solution.</b> However, concentrations of sodium and chloride {{are similar to those}} of normal plasma to prevent loss. Sodium bicarbonate is added in a higher concentration than plasma to correct blood acidity. A small amount of glucose is also commonly used.|$|R
40|$|The {{results of}} the {{randomized}} trial by Fan et al. suggest that ‘biocompatible’ peritoneal <b>dialysis</b> <b>solutions</b> have no major advantage over standard solutions in peritoneal dialysis patients in relation to residual renal function (RRF) and technique survival. The possible effect of more biocompatible peritoneal <b>dialysis</b> <b>solutions</b> on RRF should be tested in patients starting peritoneal dialysis programs with relatively well-preserved RRF. When RRF is already very poor, it is very unlikely that a more biocompatible peritoneal dialysis solution can preserve highly damaged and sclerotic kidneys...|$|E
40|$|As THE USE of peritoneal {{dialysis}} {{has become more}} widespread, reports of solution-related complications have continued to mount. In an earlier issue of this journal, Gault and associates (1) clearly related most of these complications to inappropriate choice or use of <b>dialysis</b> <b>solutions.</b> In the same issue, Tenckhoff (2) surveyed the choice of peritoneal <b>dialysis</b> <b>solutions</b> and questioned the safety and content {{of some of the}} avail-able solutions. Gault and his associates suggested, and Tenckhoff agreed, that a suitable group of physicians should get together and make specific recommendation...|$|E
40|$|International audienceTo {{investigate}} the coagulant and fibrinolytic potential of peritoneal macrophages, after short-term exposure to <b>dialysis</b> <b>solutions</b> intraperitoneal (IP) injection of these hyperosmolar glucose solutions {{was performed in}} rats. During the 72 -hour postinjection period, the <b>dialysis</b> <b>solutions</b> and, as controls, Ringer's lactate and Ringer's lactate-glucose all induced a similar {{increase in the number}} of polymorphonuclear cells and macrophages within a maximum of 24 or 48 hours after their IP injection. These findings demonstrate that IP injection of any dialysis solution results in a moderate non-specific inflammatory cell harvesting. Compared with activity induced by the control solutions, no significant increase of procoagulant and fibrinolytic activities, identified respectively by the presence of thromboplastin and plasminogen activator, was observed in peritoneal macrophages obtained 48 hours after injection of the solution with the highest glucose concentration. However, the level of procoagulant activity could increase as a result of different manufacturers' processing of the solutions. That the basal level of macrophage functions may be modified suggests that this cell may initiate coagulolytic conditions in the peritoneal cavity, especially in the course of IP injection of <b>dialysis</b> <b>solutions.</b> To {{investigate the}} coagulant and fibrinolytic potential of peritoneal macrophages, after short-term exposure to <b>dialysis</b> <b>solutions</b> intraperitoneal (IP) injection of these hyperosmolar glucose solutions was performed in rats. During the 72 -hour postinjection period, the <b>dialysis</b> <b>solutions</b> and, as controls, Ringer's lactate and Ringer's lactate-glucose all induced a similar {{increase in the number of}} polymorphonuclear cells and macrophages within a maximum of 24 or 48 hours after their IP injection. These findings demonstrate that IP injection of any dialysis solution results in a moderate non-specific inflammatory cell harvesting. Compared with activity induced by the control solutions, no significant increase of procoagulant and fibrinolytic activities, identified respectively by the presence of thromboplastin and plasminogen activator, was observed in peritoneal macrophages obtained 48 hours after injection of the solution with the highest glucose concentration. However, the level of procoagulant activity could increase as a result of different manufacturers' processing of the solutions. That the basal level of macrophage functions may be modified suggests that this cell may initiate coagulolytic conditions in the peritoneal cavity, especially in the course of IP injection of <b>dialysis</b> <b>solutions...</b>|$|E
40|$|Continuous {{ambulatory}} {{peritoneal dialysis}} (CAPD) is the continuous presence of <b>dialysis</b> <b>solution</b> in the peritoneal cavity except for brief periods of fluid exchanges. Long-dwell exchanges allow equilibration of small molecular-weight solutes between plasma and dialysate, so that clearances of these solutes are essentially equal to drainage volumes {{in a particular}} period. Originally five exchanges with 2 liters of <b>dialysis</b> <b>solution</b> were used, yielding daily drainage volumes of 10. 9 to 11. 7 liters [1]. Oreopoulos et al [2] found four 2 -liter exchanges per day sufficient in most patients to achieve good biochemical control of uremia. Increasing the volume of <b>dialysis</b> <b>solution</b> instilled into the peritoneal cavity would augment efficiency of dialysis with the same frequency of exchanges or would allow the number of exchanges to be reduced yet retain the efficiency. In the present study, we used three exchanges per day with 2. 5 liters of <b>dialysis</b> <b>solution.</b> Mainly three concentrations of glucose were used: 1. 5 %, 2. 4 %, and 3. 3 %. Occasionally, a <b>dialysis</b> <b>solution</b> with a 4. 2 % glucose concentration was used. The total exchange time (diffusion time, cycle time) varied from 2 to 14 hours. The aim of this preliminary study was to ascertain whether such a volume instilled into the peritoneal cavity could be tolerated by patients and could yield sufficient ultrafiltration...|$|R
40|$|Background: Peritoneal {{function}} {{tests are}} performed in peritoneal dialysis (PD) patients to characterize peritoneal membrane status. A low pH/high glucose degradation prod-uct (GDP) <b>dialysis</b> <b>solution</b> {{is used as}} the test solution. The objective {{of the present study}} was to compare a 3. 86 % glu-cose, low pH/high GDP <b>dialysis</b> <b>solution</b> (pH 5. 5) with a 3. 86 % glucose, normal pH/low GDP <b>dialysis</b> <b>solution</b> (pH 7. 4) in assessments of peritoneal membrane function. ¤ Methods: Two standard peritoneal permeability analyses (SPA) were performed in 10 stable PD patients within 2 weeks. One SPA was done with the 3. 86 % low pH/high GDP solution, and the other with the 3. 86 % normal pH/low GDP solution. The sequence of the two tests was randomized. ¤ Results: Fluid transport parameters and glucose absorp-tion were not different between the two groups. No differ...|$|R
5000|$|Dialyzer {{membranes}} {{come with}} different pore sizes. Those with smaller pore size are called [...] "low-flux" [...] {{and those with}} larger pore sizes are called [...] "high-flux." [...] Some larger molecules, such as beta-2-microglobulin, are not removed at all with low-flux dialyzers; lately, the trend has been to use high-flux dialyzers. However, such dialyzers require newer dialysis machines and high-quality <b>dialysis</b> <b>solution</b> to control the rate of fluid removal properly and to prevent backflow of <b>dialysis</b> <b>solution</b> impurities into the patient through the membrane.|$|R
40|$|Net {{removal of}} fluid and sodium {{from the body}} during peritoneal {{dialysis}} is accomplished with <b>dialysis</b> <b>solutions</b> that contain high glucose concentrations and are hyperosmolar to body fluid [1]. Commercially available peritoneal <b>dialysis</b> <b>solutions</b> contain glucose concentrations ranging from 1. 5 to 4. 25 g/dl and have osmolalities ranging from 334 to 490 mOsm/kg H 2 O. The solutions also contain concentrations of sodium, chloride, magnesium, and calcium that approach those of normal extracellular fluid. Acetate or lactate, rather than bicarbonate, is used as the nonchloride anion. Potassium may be added or, depending {{on the need for}} potassium removal, solutions may be potassium-free...|$|E
40|$|Buffer {{transport}} in peritoneal dialysis. The {{success of}} peritoneal dialysis as a robust modality of renal replacement therapy has invited {{a quest for}} ameliorations in its underlying technology aimed at enhancing patient satisfaction and preserving the central instrument of the therapy, namely the peritoneal membrane. The health and longevity of the membrane have motivated and continue to drive a series of iterative innovations in the composition, methods of production, and delivery of <b>dialysis</b> <b>solutions.</b> It {{is the purpose of}} this article to review aspects of these innovations pertaining to buffer composition in <b>dialysis</b> <b>solutions</b> and the peritoneal mechanisms of buffer transport...|$|E
40|$|Objective: Increased peritoneal {{vasculature}} {{has been}} reported in long-term peritoneal dialysis (PD), and vas-cular endothelial growth factors (VEGFs) have been found in dialysate. High concentrations of glucose or lactate, glucose degradation products (GDPs), and low pH of <b>dialysis</b> <b>solutions</b> are all possible factors in in-creased peritoneal VEGF synthesis. In this study, we in-vestigated the effects of high glucose <b>dialysis</b> <b>solutions</b> on VEGF synthesis by peritoneal vascular endothelial cells (PVECs). ¤ Methods: The PVECs were isolated from rat omen-tum and were incubated for 4 hours in three different culture media [M 199 media (control), conventional dialy-sis solutions containing 4. 25 % glucose diluted with an equal volume of M 199 media (HGD), and M 199 medi...|$|E
40|$|BACKGROUND: Peritoneal {{function}} {{tests are}} performed in peritoneal dialysis (PD) patients to characterize peritoneal membrane status. A low pH/high glucose degradation product (GDP) <b>dialysis</b> <b>solution</b> {{is used as}} the test solution. The objective {{of the present study}} was to compare a 3. 86 % glucose, low pH/high GDP <b>dialysis</b> <b>solution</b> (pH 5. 5) with a 3. 86 % glucose, normal pH/low GDP <b>dialysis</b> <b>solution</b> (pH 7. 4) in assessments of peritoneal membrane function. METHODS: Two standard peritoneal permeability analyses (SPA) were performed in 10 stable PD patients within 2 weeks. One SPA was done with the 3. 86 % low pH/high GDP solution, and the other with the 3. 86 % normal pH/low GDP solution. The sequence of the two tests was randomized. RESULTS: Fluid transport parameters and glucose absorption were not different between the two groups. No differences were found for the mass transfer area coefficients (MTACs) of low molecular weight solutes calculated over the whole dwell. However, MTAC urea in the first hour of the dwell was higher in the test done with low pH/high GDP dialysate, suggesting more peritoneal vasodilation. No difference was found in protein clearances. Sodium sieving at multiple time points during the dwell was similar with the two solutions. CONCLUSION: The results obtained with the glucose-containing normal pH/low GDP <b>dialysis</b> <b>solution</b> were similar to those obtained with the glucose-containing low pH/high GDP dialysate in assessments of peritoneal membrane functio...|$|R
3000|$|... tot, {{determine}} the final bicarbonate concentration. Therefore, a bicarbonate-free <b>dialysis</b> <b>solution</b> should remove bicarbonate from plasma, and {{allow it to}} return to a normal physiological pH as long as the strong ion difference and A [...]...|$|R
50|$|Either {{of these}} {{treatments}} {{can be given}} in outpatient dialysis units, three or more times a week, usually 3-5 hours per treatment. IHDF is used almost exclusively, {{with only a few}} centers using IHF. With both IHF or IHDF, the substitution fluid is prepared on-line from <b>dialysis</b> <b>solution</b> by running <b>dialysis</b> <b>solution</b> through a set of two membranes to purify it before infusing it directly into the blood line. In the United States, regulatory agencies have not yet approved on-line creation of substitution fluid because of concerns about its purity. For this reason, hemodiafiltration, had historically never been used in an outpatient setting in the United States.|$|R
40|$|OBJECTIVE: It {{is known}} that glucose {{concentrations}} of peritoneal <b>dialysis</b> <b>solutions</b> are detrimental to the peritoneal membrane. In {{order to determine the}} effect of glucose concentration on cytokine levels of peritoneal fluid of continuous ambulatory peritoneal dialysis (CAPD) patients, a cross-sectional study was performed...|$|E
40|$|Continuous renal {{replacement}} therapy (CRRT) {{is commonly used}} for renal support {{in the intensive care}} unit. While the risk of medication errors {{in the intensive care unit}} has been described, errors related specifically to CRRT are unknown. The purpose of this study is to characterize medication errors related to CRRT and compare medication errors that occur with manually compounded solutions versus commercially available solutions. We surveyed three separate internet-based, pediatric list serves that are commonly used for communications for programs utilizing CRRT. Data regarding CRRT practices and medication errors were recorded. Medication errors were graded for degree of severity and compared between programs using manually compounded <b>dialysis</b> <b>solutions</b> versus commercially available <b>dialysis</b> <b>solutions.</b> In a survey with 31 program responses, 18 reported medication errors. Two of the 18 were related to heparin compounding, while 16 / 18 were due to solution compounding errors. Half of the medication errors were classified as causing harm, two of which were fatal. All medication errors were reported by programs that manually compounded their <b>dialysis</b> <b>solutions.</b> Medication errors related to CRRT are associated with a high degree of severity, including death. Industry-based, commercially available solutions can decrease the occurrence of medication errors due to CRRT...|$|E
40|$|BACKGROUND/AIMS: Cyclosporin A (CsA) {{stimulates the}} {{development}} of fibrosis. We investigated whether CsA contributes to peritoneal alterations induced by long-term exposure to <b>dialysis</b> <b>solutions.</b> METHODS: Ten rats received peritoneal infusion of dialysis solution and oral CsA for 8 weeks. Eight received only the dialysis solution (controls). Peritoneal function was assessed at 8 weeks followed by sacrifice. The number of vessels was counted, fibrosis was assessed and hydroxyproline was determined. PCR was performed for vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF) and transforming growth factor-beta (TGF-beta). RESULTS: Histology revealed more fibrosis, hydroxyproline and vessels (thick walled) in CsA-exposed animals. Peritoneal transport was not different. The mRNA content of TGF-beta, CTGF and VEGF was higher in CsA. CONCLUSION: CsA combined with exposure to <b>dialysis</b> <b>solutions</b> was associated with increased peritoneal fibrosis and angiogenesi...|$|E
50|$|The {{pathophysiology}} of pseudoporphyria {{associated with}} hemodialysis {{has not been}} fully explained. Aluminum hydroxide has been implicated in hemodialysis-associated pseudoporphyria. Aluminum hydroxide is found in <b>dialysis</b> <b>solution</b> and {{has been shown to}} produce a porphyrialike disorder after long-term administration in rats.|$|R
40|$|Conclusions: Long-term {{intraperitoneal}} {{exposure to}} acidic <b>dialysis</b> <b>solution</b> produced features typical of EPS. Acidic <b>dialysis</b> <b>solution</b> induces {{activation of the}} peritoneal renin– angiotensin system and progression of peritoneal fibro-sis. For the peritoneum undergoing peritoneal dialysis, ARB protects against progression of peritoneal fibrosis and peritoneal adhesions. Perit Dial Int 2008; 28 (S 3) :S 83 –S 87 www. PDIConnect. com KEY WORDS: Renin–angiotensin system; angiotensin type 1 receptor blocker; ARB; peritoneal fibrosis; en-capsulating peritoneal sclerosis; EPS. Encapsulating peritoneal sclerosis (EPS) is one ofthe most serious complications for the patient on peritoneal dialysis because it causes high morbidity and mortality from bowel obstruction (1 – 6). Several factors may induce this serious condition (peritonitis...|$|R
40|$|We {{studied the}} percent {{delivery}} of insulin from CAPD <b>dialysis</b> <b>solution</b> bags used {{with and without}} the Peridex bacteriological filter. The studies were done in vitro using 125 I trace. labelled insulin. The data demonstrate {{that most of the}} insulin added to bags of <b>dialysis</b> <b>solution</b> during CAPD is delivered into the peritoneal cavity. The mean (&plusmn; S. D.) amount of insulin delivered for the trials without filters was 99 (&plusmn; 5) %. For the group with filters, the mean was 75 (&plusmn; 8) %. The difference was statistically significant (P < 0. 001). Also, a statistically significant (P < 0. 03) difference was observed be Key words: insulin delivery in CAPD, CAPD, bacteriological filter...|$|R
40|$|The {{widespread}} use of calcium carbonate as a phosphate binder is limited by its tendency to develop hypercalcemia in some patients using effective dosages needed to control hyperphosphatemia. Most common continuous ambulatory peritoneal dialysis (CAPD) regi mens using <b>dialysis</b> <b>solutions</b> containing 3. 5 mEqlL of calcium result in net absorption of calcium from the dialysis solution and, hence {{limit the amount of}} oral calcium that can be administered. Peritoneal <b>dialysis</b> <b>solutions</b> with reduced calcium levels are needed for effective use of CaCO 3 to control hyperphosphatemia in some dialysis patients. KEY WORDS: Calcium; peritoneal dialysis solutions; calcium carbonate; hyperphosphatemia. I t is widely recognized that phosphate retention plays a critical {{role in the development of}} secondary hyperparathyroidism and osteitis fibrosa in end-stage renal disease (1, 2). Hyperphosphatemia in patients with chroni...|$|E
40|$|Continuous {{exposure}} of the peritoneal membrane to high glucose <b>dialysis</b> <b>solutions</b> can produce functional alterations in this membrane. We studied the toxic effects of high glucose (50 mmol/L and 83 mmol/L) and its reversal by atorvastatin (0. 5 - 5 μmol/L) on cultures of rat peritoneal mesothelial cells (PMCs). status: publishe...|$|E
40|$|This section {{includes}} {{topics that}} {{are covered in}} varying degrees in pharmacy programmes around the world. Microbiology, extemporaneous compounding, regulatory affairs and packaging are integral components of drug development and the manufacturing process. A number of pharmaceutical preparations such as parenteral products, ophthalmic formulations, <b>dialysis</b> <b>solutions</b> and implants are required to be sterile...|$|E
40|$|Convection {{does not}} govern plasma to dialysate {{transport}} of protein. The dependence of protein clearance on molecular size during peritoneal dialysis {{can be explained}} by assuming that either convection or diffusion is the major mechanism governing plasma to dialysate transport of protein. If convection is the predominant transport mechanism, then plasma-to-dialysate transport rates for protein should not decrease when the protein concentration in the instilled <b>dialysis</b> <b>solution</b> is increased. In the present study, plasma-to-dialysate transport rates for fluorescein-labeled protein tracers, α-lactalbumin and immunoglobulin G (IgG), were determined during a six hour isotonic exchange (25 ml/kg) in New Zealand White rabbits. The protein tracers were continuously infused into the bloodstream to keep plasma concentrations relatively constant, and transperitoneal transport rates were determined either with or without tracer protein added to the instilled <b>dialysis</b> <b>solution.</b> Plasma-to-dialysate transport rates were greater for α-lactalbumin than for IgG as expected based on the molecular size of these proteins. Transport rates for both α-lactalbumin and IgG decreased when tracer protein was added to the instilled <b>dialysis</b> <b>solution.</b> The present observations do not support convection as the major mechanism governing plasma to dialysate transport of protein during peritoneal dialysis...|$|R
50|$|In peritoneal dialysis, {{wastes and}} water {{are removed from}} the blood inside the body using the {{peritoneum}} as a natural semipermeable membrane. Wastes and excess water move from the blood, across the peritoneal membrane, and into a special <b>dialysis</b> <b>solution,</b> called dialysate, in the abdominal cavity.|$|R
40|$|The most {{important}} challenge in peritoneal dialysis (PD) is long-term preservation of peritoneal membrane structure and function. Introduction of dialysis fluids into the peri-toneal cavity induces changes. These changes {{are related to}} duration of dialysis, occurrence of peritonitis and compo-nents of the <b>dialysis</b> <b>solution.</b> Bioincompatibility is consid-ered to be the major cause {{of the development of}} morpho...|$|R
40|$|Objective To {{compare the}} {{occurrence}} of hypoglycemia during hemodialysis in chronic kidney disease diabetic patients who present different levels of pre-dialysis glycemia both when using <b>dialysis</b> <b>solutions</b> with and without glucose. Subjects and methods Twenty type 2 diabetic patients in maintenance hemodialysis were submitted to three dialysis sessions (at a 7 -day interval each) with <b>dialysis</b> <b>solutions</b> without glucose, with glucose at 55 mg/dL, and at 90 mg/dL subsequently. Blood glucose levels were measured immediately pre-dialysis and at 4 moments during the session, and values under 70 mg/dL were considered as hypoglycemia. Results Average pre-dialysis glycemia was lower in those who presented intra-dialytic hypoglycemia than in those who did not, both in glucose-free (140. 4 &# 177; 50. 7 vs. 277. 7 &# 177; 91. 0 mg/dL; p = 0. 005; 95 %CI: 46. 4 to 228. 1) and in glucose 55 mg/dL (89. 5 &# 177; 10. 6 vs. 229. 7 &# 177; 105. 0 mg/dL; p < 0. 05; 95 %CI: 9. 8 to 270. 5). In patients with pre-dialysis glycemia under 140 mg/dL, average intradialytic glycemia was significantly lower than pre-dialysis glycemia only when using glucose-free dialysate (p < 0. 0001; 95 %CI: 29. 9 to 56. 0 - t-test). Hypoglycemia during dialysis was observed only when using glucose-free or glucose-poor <b>dialysis</b> <b>solutions.</b> Conclusions The use of glucose-free or glucose-poor dialysis solution presents {{a high risk of}} intradialytic hypoglycemia in diabetic renal patients, especially in those with presumed better glycemic control...|$|E
40|$|A {{mouse model}} of surgically induced renal failure was {{utilized}} {{to investigate the}} pathogenesis of Staphylococcus epidermidis peritonitis which is a frequent and serious complication of continuous ambulatory peritoneal dialysis (CAPD). Compared to sham-operated controls, chronically uremic mice were more susceptible to intraperitoneal S. epidermidis inoculation, presenting decreased survival time and survival (10 $ sp 9 $ cfu, 10 $ sp 8 $ cfu), delayed bacterial clearance and attenuated peritoneal inflammatory response (10 $ sp 6 $ cfu). In mice bearing a peritoneal catheter implant, the catheter was a preferred site for peritoneal bacterial persistence up to one month after intracatheter inoculation. Despite in vitro cytotoxicity of commercial peritoneal <b>dialysis</b> <b>solutions</b> toward peritoneal leucocytes, repeated peritoneal instillation of <b>dialysis</b> <b>solutions</b> did not influence S. epidermidis recoveries following inoculation. Although the mouse preparation did not undergo peritoneal dialysis, these studies nevertheless demonstrate that chronic uremia and the peritoneal catheter may be important etiological factors {{in the development and}} persistence of CAPD peritonitis...|$|E
40|$|We {{studied the}} {{influence}} of various peritoneal dialysis (PD) solutions mixed with nutrient broth on the growth of Proteus rettgeri Sanelli "in vitro". The volume of the nutrient broth was reduced progressively and was replaced either by water (control) or by peritoneal <b>dialysis</b> <b>solutions</b> to make up 10 %- 25 %- 50 % 75 % of the total initial volume. Bacterial growth was enhanced {{in the presence of}} the PD solutions, particularly those containing lactate. When the nutrient broth was pre-pared directly with the PD solutions, bacterial growth again was stimulated in fluids containing lactate and hypertonic glucose. These results indicate that PD solutions, in the presence of even small amounts of nutrient broth, are a good growth medium for Proteus. In the last few years various protocols have been developed for treating peritonitis in CAPD patients. Continuous lavage has been given up, and most centers use the standard pro Key words: Continuous ambulatory peritoneal dialysis (CAPD), peritoneal <b>dialysis</b> <b>solutions,</b> bacterial growth, peritoniti...|$|E
40|$|Although {{the number}} of new drug {{shortages}} has been lower in recent years than in the past, severe shortages have occurred that have affected large numbers of patients. A new law entitled the Food and Drug Administration Safety and Innovation Act was enacted in July of 2012, which requires companies to notify the Food and Drug Administration of anticipated shortages. This notification requirement has allowed the Food and Drug Administration towork closelywithmanufacturers earlier tomitigate and, often, prevent shortages. However, not all shortages are able to be prevented, and the shortage of peritoneal <b>dialysis</b> <b>solution</b> is one that has had a significant effect on patients. The Food andDrug Administration continues to use all available tools to address this shortage with manufacturers, including temporary availability of imported peritoneal <b>dialysis</b> <b>solution</b> from Ireland. Mitigating shortages is a top priority for the Food and Drug Administration, and communication with all stakeholders is essential...|$|R
40|$|This paper {{presents}} a numerical {{analysis of the}} method of internal dialysis used for studies of membrane transport in giant axons. Account is taken of the complete geometry, end effects, and finite dialyzate flow rates. Both influx and efflux experimental conditions are considered. Results place quantitative limits on system performance that are sufficiently general for use in experimental design. The completeness of solute equilibration and the uniformity of solute concentration at the axon membrane are assessed, {{as well as the}} sensitivity to <b>dialysis</b> <b>solution</b> flow rate. The effects of undialyzed axon ends on the equilibration rate and on the uniformity of concentration are determined, and the contribution of undialyzed ends to influx measurements is evaluated. Equilibration times are correlated with physical properties of axoplasm and dialysis tubing, and with <b>dialysis</b> <b>solution</b> flow rate. Numerical results confirm the general qualitative assessments of the method that are based on years of successful application...|$|R
40|$|Background: Hypophosphatemia {{occurs in}} up to 80 % of the {{patients}} during continuous renal replacement therapy (CRRT). Phosphate supplementation is time-consuming and the phosphate level might be dangerously low before normophosphatemia is re-established. This study evaluated the possibility to prevent hypophosphatemia during CRRT treatment by using a new commercially available phosphate-containing dialysis fluid. Methods: Forty-two heterogeneous intensive care unit patients, admitted between January 2007 and July 2008, undergoing hemodiafiltration, were treated with a new Gambro <b>dialysis</b> <b>solution</b> with 1. 2 mM phosphate (Phoxilium) or with standard medical treatment (Hemosol B 0). The patients were divided into three groups: group 1 (n= 14) receiving standard medical treatment and intravenous phosphate supplementation as required, group 2 (n= 14) receiving the phosphate solution as dialysate solution and Hemosol B 0 as replacement solution and group 3 (n= 14) receiving the phosphate-containing solution as both dialysate and replacement solutions. Results: Standard medical treatment resulted in hypophosphatemia in 11 of 14 of the patients (group 1) compared with five of 14 in the patients receiving phosphate solution as the dialysate solution and Hemosol B 0 as the replacement solution (group 2). Patients treated with the phosphate-containing <b>dialysis</b> <b>solution</b> (group 3) experienced stable serum phosphate levels throughout the study. Potassium, ionized calcium, magnesium, pH, pCO(2) and bicarbonate remained unchanged throughout the study. Conclusion: The new phosphate-containing replacement and <b>dialysis</b> <b>solution</b> reduces the variability of serum phosphate levels during CRRT and eliminates the incidence of hypophosphatemia...|$|R
